Analyst Rating Update on Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 17 equity analysts. Nonetheless, 12 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Edwards Lifesciences Corporation (EW) : The highest short term price target forecast on Edwards Lifesciences Corporation (EW) is $140 and the lowest target price is $105. A total of 15 equity analysts are currently covering the company. The average price of all the analysts is $125.27 with a standard deviation of $9.94.

For the current week, the company shares have a recommendation consensus of Buy.


Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $113.73 on Wednesday but the bulls could not build on the opening and the stock topped out at $114.85 for the day. The stock traded down to $113.03 during the day, due to lack of any buying support eventually closed down at $113.36 with a loss of -0.19% for the day. The stock had closed at $113.58 on the previous day. The total traded volume was 901,939 shares.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.